Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06480591 · ClinicalTrials.gov registry record
Evaluation of the Pathobiology of CALR-mutated MPN Cells
A clinical trial of Myeloproliferative Neoplasm, sponsored by Wake Forest University Health Sciences.
- Recruiting
- Registry status
- 35
- Enrollment target
- 2
- Study locations
NCT06480591: Recruiting study of Myeloproliferative Neoplasm, sponsored by Wake Forest University Health Sciences.
NCT06480591 is a study of Myeloproliferative Neoplasm that is actively recruiting participants, run by Wake Forest University Health Sciences. The registered enrollment target is 35 participants, below the 84-participant average among 40 other Myeloproliferative Neoplasm trials with a reported enrollment target (58% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06480591, a study of Myeloproliferative Neoplasm, is actively recruiting participants, sponsored by Wake Forest University Health Sciences.
- RECRUITING
- Registry status
- 35 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to understand why there is a greater risk of thrombosis in patients who have the JAK2 mutation as compared to those with CALR mutations.
Primary Outcome
Percentages of mononuclear cells expressing TLR 2 and TLR 4 will be calculated for each participant.
Conditions Studied
Interventions
- OTHER Blood Draw
Study Locations (2)
North Carolina
- Atrium Health Levine Cancer - Charlotte
- Wake Forest Baptist Comprehensive Cancer Center - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2025-01-21 |
| Est. Completion | 2026-09 |
What NCT06480591 shows while recruiting
NCT06480591 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 35 participants, a relatively small participant target, below the 84-participant average among 40 other Myeloproliferative Neoplasm trials with a reported enrollment target (58% lower).
The record links to 1 condition, with Myeloproliferative Neoplasm appearing as the primary indexed condition, and to 1 intervention - of which Blood Draw is the first listed.
NCT06480591 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT06480591 about?
NCT06480591 is a clinical study titled "Evaluation of the Pathobiology of CALR-mutated MPN Cells". The purpose of this study is to understand why there is a greater risk of thrombosis in patients who have the JAK2 mutation as compared to those with CALR mutations.
What is the current status of trial NCT06480591?
This trial is currently recruiting. The enrollment target is 35 participants. The study started on 2025-01-21. Estimated completion is 2026-09.
What conditions does trial NCT06480591 study?
This clinical trial studies the following conditions: Myeloproliferative Neoplasm.
What interventions are being tested in trial NCT06480591?
The interventions under investigation include: Blood Draw (OTHER).
Who is sponsoring clinical trial NCT06480591?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06480591 being conducted?
This trial has 2 study locations across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myeloproliferative Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06480591's enrollment target sits among peer trials
35 26th of 40 higher than 13 of 40 other Myeloproliferative Neoplasm trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Myeloproliferative Neoplasm trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Brain MRF in Children, Adolescents and Young Adults With Acute Leukemia
RECRUITING · NA
-
Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms
RECRUITING · Phase 2
-
Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)
RECRUITING · Phase 2
-
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
RECRUITING
-
CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
RECRUITING · Phase 2
-
Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01697371 · 35 participants · NA
Proton Therapy in the Treatment of Liver Metastases
- NCT01940757 · 35 participants · Phase 1
Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae
- NCT02235857 · 35 participants · NA
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
- NCT02637934 · 35 participants · Phase 1
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI